Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: Focus on lasofoxifene

Clinical Interventions in Aging

Volumn 5, Issue 1, 2010, Pages 19-29

  Gennari, Luigi ^a   Merlotti, Daniela ^a   Nuti, Ranuccio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Bone density; Fractures; Lasofoxifene; Menopause; Postmenopausal osteoporosis; SERM

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; FABLYN; LASOFOXIFENE; MEDROXYPROGESTERONE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; BONE MASS; BONE TURNOVER; BREAST CANCER; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ESTROGEN THERAPY; FRACTURE; HEART INFARCTION; HORMONE ACTION; HOT FLUSH; HUMAN; LEG CRAMP; LOW DRUG DOSE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK REDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VAGINA ATROPHY; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 77951155962     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/cia.s6083     Document Type: Review

References (82)

1. Osteoporosis Prevention, Diagnosis, and Therapy Consensus Statement 2000. JAMA. 2001;285:785-795.
2. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010-2018.
3. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38:S4-S9.
4. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761-1767.
5. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-1733.
6. Ross PD. Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med. 1996;156:1399-1411.
7. Dennison E, Mohamed MA, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin North Am. 2006;32:617-629.
8. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts and prospects. J Clin Invest. 2005;115:3318-3325.
9. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980;2(8205): 1151-1154.
10. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet. 1993;341:72-75.
11. Hui SL, Slemenda CW, Carey MA, Johnston CC. Choosing between predictors of fractures. J Bone Miner Res. 1995;10:1816-1822.
12. Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250-2261.
13. Martin TJ, Seeman E. Bone remodeling: its local regulation and the emergence of bone fragility. Best Pract Res Clin Endo Endocrinol Metab. 2008;22:701-722.
14. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endo Rev. 2002;23:279-302.
15. Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun. 2005;328:688-696.
16. Pacifici R. Mechanisms of estrogen action in bone. In: Bilezikian JP, Raisz LG, Martin TJ, editors. Principles of Bone Biology, 3rd ed. USA: Elsevier Inc; 2008. pp. 921-933.
17. Bush TL, Wells HB, James MK, et al. Effects of hormone therapy on bone mineral density-results from the postmenopausal estrogen/ progestin interventions (PEPI) trial. JAMA. 1996;276:1389-1396.
18. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-1477.
19. Jackson RD, Shidham S. The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative. Current Osteoporosis Reports. 2007;5(4):153-159.
20. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-941.
21. Manson JE, Hsia J, Johnson KC, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
22. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
23. Vassilopoulou-Sellin R. Breast cancer and hormonal replacement therapy. Ann N Y Acad Sci. 2003;997:341-350.
24. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American menopause society. Menopause. 2008;15(4):584-602.
25. Cho CH, Nuttall ME. Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Expert Opin Emerg Drugs. 2001;6:137-154.
26. Jordan VC. Chemosuppression of breast cancer with tamoxifen-laboratory evidence and future clinical investigations. Cancer Investigation. 1988;6:589-595.
27. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer (Eighth Cain Memorial award lecture). Cancer Res. 1990;50:4177-4189.
28. Avioli LV. SERM Drugs for the prevention of osteoporosis. Trends Endocrinol Metab. 1999;10:317-319.
29. Riggs L, Hartmann LC. Selective Estrogen-Receptor Modulators-Mechanisms of Action and Application to Clinical Practice. N Engl J Med. 2003;348:618-629.
30. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753-758.
31. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95:927-937.
32. Paige LA, Christensen DJ, Grøn H, et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ERa and ERb. Proc Natl Acad Sci U S A. 1999;96:3999-4004.
33. Nilsson S, Koehler KF. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol. 2005;96:15-25.
34. Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging. 2007;24:361-379.
35. Gennari L, Merlotti D, De Paola V, Martini G, Nuti R. Bazedoxifene for the prevention of postmenopausal osteoporosis. Ther Clin Risk Manag. 2008a;4(6):1229-1242.
36. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
37. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res. 1998;13:1747-1754.
38. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637-645.
39. Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat. 1987;10:31-35.
40. Love RR, Barden HS, Mazess RB, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med. 1994;154:2585-2588.
41. Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab. 2000;85:2197-2202.
42. Weinstein RS, Parfitt AM, Marcus R, et al. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int. 2003;14:814-822.
43. Gennari L, Merlotti D, De Paola V, Nuti R. Raloxifene in breast cancer prevention. Expert Opin Drug Saf. 2008b;7:259-270.
44. Gennari L, Merlotti D, Valleggi F, Nuti R. Ospemifene use in postmenopausal women. Expert Opin Investig Drugs. 2009;18(6):839-849.
45. Rosati RL, Da Silva Jardine P, Cameron KO. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem. 1998;41:2928-2931.
46. Ke HZ, Paralkar VM, Grasser WA. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology. 1998;139:2068-2076.
47. Gennari L, Merlotti D, Martini G, Nuti R. Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. Expert Opin Investig Drugs. 2006a;15: 1091-1103.
48. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet. 2003;42:361-372.
49. Gennari L. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs Today (Barc). 2006b;42:355-367.
50. Moller R, Fisher J, Taylor A, et al. Effect of Food on the Pharmacokinetics of Lasofoxifene, in Healthy Postmenopausal Women. J Bone Miner Res. 2004;19:Abstract SU487.
51. Gardner M, Nishizawa Y, Wei G, et al. A Single-Dose Pharmacokinetic Study of Lasofoxifene in Japanese and Caucasian Postmenopausal Women. J Bone Miner Res. 2004;19:Abstract M469.
52. Gardner M, Taylor A, Wei G, et al. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women. J Clin Pharmacol. 2006;46:52-58.
53. Fountaine RJ, Nishizawa Y, Wei G, Dogolo L, Calcagni A, Gardner MJ. Clinical pharmacology of lasofoxifene in Japanese and white postmenopausal women. J Clin Pharmacol. 2006;46:693-699.
54. Katzenellenbogen JA. D-1,2-Dyaril-3,4-dihydronaphthalenes: photofluorogenic ligands for the estrogen receptor. J Steroid Biochem. 1985;23:929-937.
55. Jhonson KA, Gardner MJ, Prakash C. In vivo and in vitro metabolites of a next-generation selective estrogen receptor modulator, lasofoxifene, in humans. Drug Metab Rev. 2004;36:246.
56. Roman D, Bramson C, Ouellet D, et al. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women. J Clin Pharmacol. 2005;45:1407-1412.
57. Moller RA, Fisher JM, Taylor AE, et al. Effects of Steady-State Lasofoxifene on CYP2D6- and CYP2E1-Mediated Metabolism. Ann Pharmacother. 2006;40:32-37.
58. Bramson C, Ouellet D, Roman D, et al. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment. J Clin Pharmacol. 2006;46:29-36.
59. Ouellet D, Bramson C, Carvajal-Gonzalez S, Roman D, Randinitis E, Remmers A, et al. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. Br J Clin Pharmacol. 2006;61:741-745.
60. Ke HZ, Qi H, Chidsey-Frink KL, et al. Effects of different dose regimens of lasofoxifene (CP-336,156) in preventing bone loss in ovariectomized rats. J Bone Miner Res. 2000a;15:S1-S310.
61. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology. 2004;145:1996-2005.
62. Ke HZ, Qi H, Crawford DT, et al. Lasofoxifene (CP-336-156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology. 2000b; 141:1338-1344.
63. Ke HZ, Oi H, Chidsey-Frink KL, et al. Lasofoxifene (CP-336-156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J Bone Miner Res. 2001;16:765-773.
64. Kharode YP, Green PD, Marzolf JT, et al. Comparison of the effects of bazedoxifene, raloxifene, lasofoxifene and risedronate, co-treatment on h-PTH-induced reversal of established osteopenia in ovariectomized rats. J Bone Miner Res. 2003;18:S273.
65. Cohen LA, Pittman B, Wang CX, et al. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cancer Res. 2001;61:8683-8688.
66. Gennari L, Merlotti D, De Paola V, Nuti R. Lasofoxifene: the evidence of its therapeutic value in osteoporosis. Core Evidence. 2009;4:113-129.
67. Chesworth R, Zawistoski MP, Lefker BA, et al. Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists. Bioorganic and Medicinal Chemistry Letters. 2004;14:2729-2733.
68. Lee A, Radecki D, Wolter K, et al. Lasofoxifene Phase 2 and Phase 3 Clinical Trial Design and Strategy. J Bone Miner Res. 2005;20:Abstract M384.
69. Day W, Martel J, Lee A. Lasofoxifene phase 2 dose response analysis in postmenopausal women. J Bone Miner Res. 2005;20:Abstract M385.
70. Moffett AH, Ettinger M, Bolognese M, et al. Lasofoxifene, a Next Generation SERM, is Effective in Preventing Loss of BMD and Reducing LDL-C in Postmenopausal Women. J Bone Miner Res. 2004;19: Abstract SA426.
71. Portman DJ, Moffett AH, Bachman GA, West C, Symons J. Lasofoxifene, a selective estrogen receptor modulator, improves objective measures of vaginal atrophy. Obstetrics and Gynecology. 2004;103:25S-26S.
72. Ettinger M, Schwartz E, Emkey R, et al. Lasofoxifene: a next generation selective estrogen receptor modulator (SERM) in the prevention of bone loss in postmenopausal women. 86th Annual Meeting of the Endocrine Society; 2004 June 16-19; New Orleans, LA.
73. Lingand pharmaceutical Internetional Inc., Annual Report 2000. Available from http//investors.ligand.com.
74. McClung M, Portman D, Emkey R, et al. Comparison of the extraskeletal effects of lasofoxifene and raloxifene. J Bone Miner Res. 2004;19: Abstract SA423.
75. McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause. 2006;13:377-386.
76. McClung M, Siris E, Cummings S, et al. Lasofoxifene Increased BMD of the Spine and Hip and Decreased Bone Turnover Markers in Postmenopausal Women with Low or Normal BMD. J Bone Miner Res. 2005;20:Abstract F429.
77. Davidson M, Moffett A, Welty F, et al. Extraskeletal Effects of Lasofoxifene on Postmenopausal Women. J Bone Miner Res. 2005;20: Abstract SA428.
78. Eastell R, Reid DM, Vukicevic S, et al. The Effects of Lasofoxifene on Bone Turnover Markers: the PEARL Trial. J Bone Miner Res. 2008;23: Abstract 1287.
79. Glover SJ, Rogers A, Gossiel F, Eastell R. A randomized double blinded controlled trial of individual response in biochemical markers of bone turnover to lasofoxifene therapy. J Bone Miner Res. 2008;23: Abstract M507.
80. Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL Trial. J Bone Miner Res. 2008;23:Abstract 1288.
81. European Medicines Agency, Pre-Authorisation Evaluation of Medicines for Human Use. Committee for Medicinal Products for Human Use summary of positive opinion for Fablyn. London, 2008 December 18. Doc Ref EMEA/CHMP/609979/2008.
82. Stevenson N, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005; 9:1-160.